5-MAPB

Use and effects

5-MAPB is an entactogen and has been described by Matthew Baggott as the MDMA analogue so far known that has the closest effects and so-called "magic" to MDMA itself. Other analogues that lack the full quality of MDMA include MBDB, methylone, 6-APDB, 5-APDB, 6-APB, 5-APB, MDAT, and MDAI, among others.

In addition to its use on its own, 5-MAPB, along with the related entactogen MDAI, is employed as a component of the MDMA-mimicking Borax combo.

Interactions

Pharmacology

Pharmacodynamics

5-MAPB acts as a serotonin–norepinephrine–dopamine releasing agent with values for induction of monoamine release of 64nM for serotonin, 24nM for norepinephrine, and 41nM for dopamine using rat brain synaptosomes. It is also a partial agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors. In addition, unlike MDMA, it is a potent agonist of the serotonin 5-HT1B receptor.

5-MAPB has been marketed as a less- or non-neurotoxic alternative to MDMA. However, 5-MAPB has been found to be a dose-dependent serotonergic neurotoxin in rodents similarly to MDMA, and might also be a dopaminergic neurotoxin.

Pharmacokinetics

Little formal knowledge exists on 5-MAPB. It does not form the α-methyldopamine metabolite that contributes to the neurotoxicity of MDMA or MDA. A study in rats indicated that the major metabolites of 5-MAPB are 5-APB and 3-carboxymethyl-4-hydroxymethamphetamine.

History

5-MAPB was first encountered as a novel designer drug in 2013 and described in the scientific literature in 2014.

Society and culture

Legal Status

Canada

5-MAPB is not listed itself in the CDSA but since it is structurally related to MDMA it may be considered illegal in Canada, although this has not been tested in court.

China

As of October 2015, 5-MAPB is a controlled substance in China.

Finland

Scheduled in the "government decree on psychoactive substances banned from the consumer market".

Luxembourg

As of July 2021, 5-MAPB is not cited in the list of prohibited substances. Therefore, it is still a legal substance.

United Kingdom

5-MAPB was originally banned in the UK in June 2013 under a Temporary class drug order. On March 5, 2014, the UK Home Office announced that 5-MAPB would be made a class B drug on 10 June 2014 alongside every other benzofuran entactogen and many structurally related drugs.

References

References

1. (4 June 2013). "Temporary class drug order report on 5-6APB and NBOMe compounds". UK Home Office.
2. (6 March 2024). "Better Than Ecstasy: Progress in Developing a Novel Class of Therapeutic with Matthew Baggott, PhD.".
3. (23 June 2023). "Beyond Ecstasy: Progress in Developing and Understanding a Novel Class of Therapeutic Medicine". [[Multidisciplinary Association for Psychedelic Studies]].
4. (28 November 2023). "POD 92: Understanding and Improving MDMA with Dr. Matthew Baggott". Patreon.
5. (14 December 2022). "Borax Combo (Synonyms: Blue Bliss)". National Association of Drug Diversion Investigators (NADDI).
6. (2022). "Handbook of Substance Misuse and Addictions". Springer International Publishing.
7. (May 2021). "Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy". Journal of Psychopharmacology.
8. (December 2020). "The psychoactive aminoalkylbenzofuran derivatives, 5-APB and 6-APB, mimic the effects of 3,4-methylenedioxyamphetamine (MDA) on monoamine transmission in male rats". Psychopharmacology (Berl).
9. (April 2017). "Combined in vitro and in silico approaches to the assessment of stimulant properties of novel psychoactive substances - The case of the benzofuran 5-MAPB". Progress in Neuro-Psychopharmacology & Biological Psychiatry.
10. (January 2017). "Neurochemical binding profiles of novel indole and benzofuran MDMA analogues". Naunyn Schmiedebergs Arch Pharmacol.
11. "Advantageous benzofuran compositions for mental disorders or enhancement".
12. "Advantageous benzofuran compositions for mental disorders or enhancement".
13. (2022). ["314.03 / RR6 - Locomotor stimulant effects and persistent serotonin depletions following 1-Benzofuran-5-yl)-N-methylpropan-2-amine (5-MAPB) treatment in Sprague-Dawley rats".
14. (January 2017). "Neurochemical binding profiles of novel indole and benzofuran MDMA analogues". Naunyn-Schmiedeberg's Archives of Pharmacology.
15. (April 1991). "Major metabolites of (+/-)3,4-methylenedioxyamphetamine (MDA) do not mediate its toxic effects on brain serotonin neurons". Brain Research.
16. (April 1997). "2,5-Bis-(glutathion-S-yl)-alpha-methyldopamine, a putative metabolite of (+/-)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations". European Journal of Pharmacology.
17. (December 1978). "Acute and chronic administration of alpha-methyldopa: regional levels of endogenous and alpha-methylated catecholamines in rat brain". European Journal of Pharmacology.
18. (February 2015). "Benzofuran analogues of amphetamine and methamphetamine: studies on the metabolism and toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC-MS and LC-(HR)-MS(n) techniques". Analytical and Bioanalytical Chemistry.
19. (2014). "New phenethylamines in Europe". Drug Test Anal.
20. https://isomerdesign.com/bitnest/external/EMCDDA/New-Drugs-In-Europe-2013
21. (2014-12-12). "Schedule I". Government Of Canada.
22. (27 September 2015). "关于印发《非药用类麻醉药品和精神药品列管办法》的通知". China Food and Drug Administration.
23. "Valtioneuvoston asetus kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista | 1130/2014 | Lainsäädäntö | Finlex".
24. "Loi du 19 février 1973 concernant la vente de substances médicamenteuses et la lutte contre la toxicomanie.". Journal officiel du Grand-Duché de Luxembourg.
25. (2013-06-04). "'NBOMe' and 'Benzofury' banned". UK Home Office.
26. UK Home Office. (2014-03-05). "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014". UK Government.